Present and Future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections
Open accessThe DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
Carbapenem-resistant Enterobacteriaceae (CRE) have become a public health threat worldwide. There are three major mechanisms by which Enterobacteriaceae become resistant to carbapenems: enzyme production, efflux pumps and porin mutations. Of these, enzyme production is the main resistance mechanism. There are three main groups of enzymes responsible for most of the carbapenem resistance: KPC (Klebsiella pneumoniae carbapenemase) (Ambler class A), MBLs (Metallo-ß-Lactamases) (Ambler class B) and OXA-48-like (Ambler class D). KPC-producing Enterobacteriaceae are endemic in the United States, Colombia, Argentina, Greece and Italy. On the other hand, the MBL NDM-1 is the main carbapenemase-producing resistance in India, Pakistan and Sri Lanka, while OXA-48-like enzyme-producers are endemic in Turkey, Malta, the Middle-East and North Africa. All three groups of enzymes are plasmid-mediated, which implies an easier horizontal transfer and, thus, faster spread of carbapenem resistance worldwide. As a result, there is an urgent need to develop new therapeutic guidelines to treat CRE infections. Bearing in mind the different mechanisms by which Enterobacteriaceae can become resistant to carbapenems, there are different approaches to treat infections caused by these bacteria, which include the repurposing of already existing antibiotics, dual therapies with these antibiotics, and the development of new ß-lactamase inhibitors and antibiotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yong, D., Toleman, M. A., Giske, C. G., Cho, H. S., Sundman, K., Lee, K., & Walsh, T. R. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00774-09 · Cited by 2,519
Carbapenemases: the Versatile β-Lactamases
Queenan, A. M., & Bush, K. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-07 · Cited by 2,499
Global Spread of Carbapenemase-producing Enterobacteriaceae
Nordmann, P., Naas, T., & Poirel, L. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1710.110655 · Cited by 2,378
Ambler, R. P. (1980) · Philosophical Transactions of the Royal Society of London. B, Biological Sciences · doi:10.1098/rstb.1980.0049 · Cited by 1,823
Yigit, H., Queenan, A. M., Anderson, G. J., Domenech-Sanchez, A., Biddle, J. W., Steward, C. D., Alberti, S., Bush, K., & Tenover, F. C. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1151-1161.2001 · Cited by 1,639
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
Munoz-Price, L. S., Poirel, L., Bonomo, R. A., Schwaber, M. J., Daikos, G. L., Cormican, M., Cornaglia, G., Garau, J., Gniadkowski, M., Hayden, M. K., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70190-7 · Cited by 1,627
Logan, L. K., & Weinstein, R. A. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw282 · Cited by 1,584
The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria
Nordmann, P., Cuzon, G., & Naas, T. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70054-4 · Cited by 1,579
Molecular mechanisms that confer antibacterial drug resistance
Walsh, C. (2000) · Nature · doi:10.1038/35021219 · Cited by 1,578
Metallo-β-Lactamases: the Quiet before the Storm?
Walsh, T. R., Toleman, M. A., Poirel, L., & Nordmann, P. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.2.306-325.2005 · Cited by 1,431
Walsh, T. R., Weeks, J., Livermore, D. M., & Toleman, M. A. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70059-7 · Cited by 1,250
Tzouvelekis, L. S., Markogiannakis, A., Psichogiou, M., Tassios, P. T., & Daikos, G. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05035-11 · Cited by 1,191
β-Lactamases and β-Lactamase Inhibitors in the 21st Century
Tooke, C. L., Hinchliffe, P., Bragginton, E. C., Colenso, C. K., Hirvonen, V. H. A., Takebayashi, Y., & Spencer, J. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.04.002 · Cited by 1,016
The global epidemiology of carbapenemase-producing Enterobacteriaceae
van Duin, D., & Doi, Y. (2017) · Virulence · doi:10.1080/21505594.2016.1222343 · Cited by 1,004
OXA-48-like carbapenemases: the phantom menace
Poirel, L., Potron, A., & Nordmann, P. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks121 · Cited by 924
Past and Present Perspectives on β-Lactamases
Bush, K. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01076-18 · Cited by 832
Plasmid-Determined AmpC-Type β-Lactamases
Philippon, A., Arlet, G., & Jacoby, G. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.1-11.2002 · Cited by 816
Carbapenem Resistance: A Review
Codjoe, F., & Donkor, E. (2017) · Medical Sciences · doi:10.3390/medsci6010001 · Cited by 746
Rodríguez-Baño, J., Gutiérrez-Gutiérrez, B., Machuca, I., & Pascual, A. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00079-17 · Cited by 704
The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide
Nordmann, P., & Poirel, L. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12719 · Cited by 679
Lauretti, L., Riccio, M. L., Mazzariol, A., Cornaglia, G., Amicosante, G., Fontana, R., & Rossolini, G. M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1584 · Cited by 677
van Duin, D., Lok, J. J., Earley, M., Cober, E., Richter, S. S., Perez, F., Salata, R. A., Kalayjian, R. C., Watkins, R. R., Doi, Y., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix783 · Cited by 655
Daikos, G. L., Tsaousi, S., Tzouvelekis, L. S., Anyfantis, I., Psichogiou, M., Argyropoulou, A., Stefanou, I., Sypsa, V., Miriagou, V., Nepka, M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02166-13 · Cited by 597
Worldwide Dissemination of the NDM-Type Carbapenemases in Gram-Negative Bacteria
Dortet, L., Poirel, L., & Nordmann, P. (2014) · BioMed Research International · doi:10.1155/2014/249856 · Cited by 501
Walther-Rasmussen, J., & Høiby, N. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki482 · Cited by 495
Bradford, P. A., Bratu, S., Urban, C., Visalli, M., Mariano, N., Landman, D., Rahal, J. J., Brooks, S., Cebular, S., & Quale, J. (2004) · Clinical Infectious Diseases · doi:10.1086/421495 · Cited by 485
Wunderink, R. G., Giamarellos-Bourboulis, E. J., Rahav, G., Mathers, A. J., Bassetti, M., Vazquez, J., Cornely, O. A., Solomkin, J., Bhowmick, T., Bishara, J., et al. (2018) · Infectious Diseases and Therapy · doi:10.1007/s40121-018-0214-1 · Cited by 461
“Stormy waters ahead”: global emergence of carbapenemases
Patel, G., & Bonomo, R. A. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00048 · Cited by 423
Motsch, J., Murta de Oliveira, C., Stus, V., Köksal, I., Lyulko, O., Boucher, H. W., Kaye, K. S., File, T. M., Brown, M. L., Khan, I., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz530 · Cited by 422
Zhanel, G. G., Lawrence, C. K., Adam, H., Schweizer, F., Zelenitsky, S., Zhanel, M., Lagacé-Wiens, P. R. S., Walkty, A., Denisuik, A., Golden, A., et al. (2018) · Drugs · doi:10.1007/s40265-017-0851-9 · Cited by 377
Evaluation of Methods To Identify the Klebsiella pneumoniae Carbapenemase in Enterobacteriaceae
Anderson, K. F., Lonsway, D. R., Rasheed, J. K., Biddle, J., Jensen, B., McDougal, L. K., Carey, R. B., Thompson, A., Stocker, S., Limbago, B., et al. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00015-07 · Cited by 355
Lomovskaya, O., Sun, D., Rubio-Aparicio, D., Nelson, K., Tsivkovski, R., Griffith, D. C., & Dudley, M. N. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01443-17 · Cited by 353
Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues
Miriagou, V., Cornaglia, G., Edelstein, M., Galani, I., Giske, C. G., Gniadkowski, M., Malamou-Lada, E., Martinez-Martinez, L., Navarro, F., Nordmann, P., et al. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.03116.x · Cited by 350
Mechanisms of envelope permeability and antibiotic influx and efflux in Gram-negative bacteria
Masi, M., Réfregiers, M., Pos, K. M., & Pagès, J.-M. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.1 · Cited by 337
Transfer of antibiotic resistance genes between gram-positive and gram-negative bacteria
Courvalin, P. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.7.1447 · Cited by 327
Carbapenemases: a problem in waiting?
Livermore, D. M., & Woodford, N. (2000) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(00)00128-4 · Cited by 323
Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent
Zhanel, G. G., Cheung, D., Adam, H., Zelenitsky, S., Golden, A., Schweizer, F., Gorityala, B., Lagacé-Wiens, P. R. S., Walkty, A., Gin, A. S., et al. (2016) · Drugs · doi:10.1007/s40265-016-0545-8 · Cited by 317
The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
Karaiskos, I., Lagou, S., Pontikis, K., Rapti, V., & Poulakou, G. (2019) · Frontiers in Public Health · doi:10.3389/fpubh.2019.00151 · Cited by 288
The Problem of Carbapenemase-Producing-Carbapenem-Resistant-Enterobacteriaceae Detection
Lutgring, J. D., & Limbago, B. M. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.02771-15 · Cited by 272
Ito, H., Arakawa, Y., Ohsuka, S., Wacharotayankun, R., Kato, N., & Ohta, M. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.4.824 · Cited by 266
Management of carbapenem-resistant Enterobacteriaceae infections
Durante-Mangoni, E., Andini, R., & Zampino, R. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.04.013 · Cited by 261
De Pascale, G., Montini, L., Pennisi, M. A., Bernini, V., Maviglia, R., Bello, G., Spanu, T., Tumbarello, M., & Antonelli, M. (2014) · Critical Care · doi:10.1186/cc13858 · Cited by 245
Hackel, M. A., Tsuji, M., Yamano, Y., Echols, R., Karlowsky, J. A., & Sahm, D. F. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01968-17 · Cited by 235
Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae
Bulik, C. C., & Nicolau, D. P. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01420-10 · Cited by 200
Carbapenem-resistant Enterobacteriaceae: A menace to our most vulnerable patients
Perez, F., & Van Duin, D. (2013) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.80a.12182 · Cited by 184
Regulation of the AcrAB-TolC efflux pump in Enterobacteriaceae
Weston, N., Sharma, P., Ricci, V., & Piddock, L. J. V. (2018) · Research in Microbiology · doi:10.1016/j.resmic.2017.10.005 · Cited by 179
Global spread of New Delhi metallo-β-lactamase 1
Hammerum, A. M., Toleman, M. A., Hansen, F., Kristensen, B., Lester, C. H., Walsh, T. R., & Fuursted, K. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70276-0 · Cited by 173
Nelson, K., Hemarajata, P., Sun, D., Rubio-Aparicio, D., Tsivkovski, R., Yang, S., Sebra, R., Kasarskis, A., Nguyen, H., Hanson, B. M., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00989-17 · Cited by 170
Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®
Blizzard, T. A., Chen, H., Kim, S., Wu, J., Bodner, R., Gude, C., Imbriglio, J., Young, K., Park, Y.-W., Ogawa, A., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.12.101 · Cited by 168
Papp‐Wallace, K. M., Nguyen, N. Q., Jacobs, M. R., Bethel, C. R., Barnes, M. D., Kumar, V., Bajaksouzian, S., Rudin, S. D., Rather, P. N., Bhavsar, S., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00091 · Cited by 168
de Jonge, B. L. M., Karlowsky, J. A., Kazmierczak, K. M., Biedenbach, D. J., Sahm, D. F., & Nichols, W. W. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03042-15 · Cited by 162
Treatment of Infections by OXA-48-Producing Enterobacteriaceae
Stewart, A. G., Harris, P. N. A., Henderson, A., & Paterson, D. L. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01195-18 · Cited by 152
Okoche, D., Asiimwe, B. B., Katabazi, F. A., Kato, L., & Najjuka, C. F. (2015) · PLOS ONE · doi:10.1371/journal.pone.0135745 · Cited by 151
Fernández, J., Guerra, B., & Rodicio, M. R. (2018) · Veterinary Sciences · doi:10.3390/vetsci5020040 · Cited by 150
Corbett, D. F., Wise, A., Langley, T., Skinner, K., Trimby, E., Birchall, S., Dorali, A., Sandiford, S. K., Williams, J., Warn, P. A., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00200-17 · Cited by 148
Haidar, G., Clancy, C. J., Chen, L., Samanta, P., Shields, R. K., Kreiswirth, B. N., & Nguyen, M. H. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00642-17 · Cited by 142
Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature
Vardakas, K. Z., Legakis, N. J., Triarides, N. A., & Falagas, M. E. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.02.001 · Cited by 139
Satlin, M. J., Kubin, C. J., Blumenthal, J. S., Cohen, A. B., Furuya, E. Y., Wilson, S. J., Jenkins, S. G., & Calfee, D. P. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00387-11 · Cited by 132
Saisho, Y., Katsube, T., White, S., Fukase, H., & Shimada, J. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02163-17 · Cited by 131
Sader, H. S., Castanheira, M., Duncan, L. R., & Flamm, R. K. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.04.012 · Cited by 131
Solomkin, J. S., Ramesh, M. K., Česnauskas, G., Novikovs, N., Stefanova, P. P., Sutcliffe, J. A., Walpole, S. M., & Horn, P. T. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01614-13 · Cited by 129
Ni, W., Han, Y., Liu, J., Wei, C., Zhao, J., Cui, J., Wang, R., & Liu, Y.-N. (2016) · Medicine · doi:10.1097/md.0000000000003126 · Cited by 127
Karlowsky, J. A., Biedenbach, D. J., Kazmierczak, K. M., Stone, G. G., & Sahm, D. F. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02286-15 · Cited by 126
Endimiani, A., Hujer, K. M., Hujer, A. M., Armstrong, E. S., Choudhary, Y., Aggen, J. B., & Bonomo, R. A. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00556-09 · Cited by 118
Walkty, A., Adam, H., Baxter, M., Denisuik, A., Lagacé-Wiens, P., Karlowsky, J. A., Hoban, D. J., & Zhanel, G. G. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02744-13 · Cited by 115
Petty, L. A., Henig, O., Patel, T. S., Pogue, J. M., & Kaye, K. S. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s150447 · Cited by 112
Sader, H. S., Rhomberg, P. R., Flamm, R. K., Jones, R. N., & Castanheira, M. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx050 · Cited by 110
Metallo beta lactamases inPseudomonas aeruginosaand Acinetobacter species
Gupta, V. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.2.131 · Cited by 99
Queenan, A. M., Shang, W., Flamm, R., & Bush, K. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01004-09 · Cited by 98
Karaiskos, I., Galani, I., Souli, M., & Giamarellou, H. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1563071 · Cited by 92
The Epidemiology, Evolution, and Treatment of KPC-Producing Organisms
Porreca, A. M., Sullivan, K. V., & Gallagher, J. C. (2018) · Current Infectious Disease Reports · doi:10.1007/s11908-018-0617-x · Cited by 86
Pharmacokinetic and pharmacodynamic evaluation of tigecycline
Giamarellou, H., & Poulakou, G. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.623126 · Cited by 78
Next-Generation Drug Discovery to Combat Antimicrobial Resistance
Niu, G., & Li, W. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2019.05.005 · Cited by 76
Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria
D’Angelo, R. G., Johnson, J. K., Bork, J. T., & Heil, E. L. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1154538 · Cited by 75
Castanheira, M., Deshpande, L. M., Woosley, L. N., Serio, A. W., Krause, K. M., & Flamm, R. K. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky344 · Cited by 75
Sheu, C., Lin, S., Chang, Y.-T., Lee, C.-Y., Chen, Y., & Hsueh, P. (2018) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2018.1436966 · Cited by 66
Routh, M. D., Zalucki, Y. M., Su, C., Long, F., Zhang, Q., Shafer, W. M., & Yu, E. W. (2011) · Advances in enzymology and related areas of molecular biology/Advances in enzymology and related subjects · doi:10.1002/9780470920541.ch3 · Cited by 65
Goessens, W. H. F., van der Bij, A. K., van Boxtel, R., Pitout, J. D. D., van Ulsen, P., Melles∗, D. C., & Tommassen, J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02459-12 · Cited by 55
Eravacycline for the treatment of intra-abdominal infections
Bassetti, M., & Righi, E. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.965253 · Cited by 54
Outbreak Caused by NDM-1- and RmtB-Producing Escherichia coli in Bulgaria
Poirel, L., Savov, E., Nazlı, A., Trifonova, A., Тодорова, И., Gergova, I., & Nordmann, P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02571-13 · Cited by 50
Oliva, A., Scorzolini, L., Castaldi, D., Gizzi, F., Angelis, M. D., Storto, M., D’Abramo, A., Aloj, F., Mascellino, M. T., Mastroianni, C. M., et al. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.10.002 · Cited by 45
Bialek-Davenet, S., Mayer, N., Vergalli, J., Duprilot, M., Brisse, S., Pagès, J., & Nicolas-Chanoine, M.-H. (2017) · Scientific Reports · doi:10.1038/s41598-017-06503-6 · Cited by 38
Current status of carbapenemases in Latin America
Maya, J. J., Ruiz, S. J., Blanco, V. M., Gotuzzo, E., Guzmán-Blanco, M., Labarca, J. A., Salles, M. J. C., Quinn, J. P., & Villegas, M. V. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2013.811924 · Cited by 35
Venditti, C. C., Nisii, C., D’Arezzo, S., Vulcano, A., Capone, A., Antonini, M., Ippolito, G., & Di, A. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s207993 · Cited by 28
Cited by
Antimicrobial Resistance: A Growing Serious Threat for Global Public Health
Salam, M. A., Al-Amin, M. Y., Salam, M. T., Pawar, J. S., Akhter, N., Rabaan, A. A., & Alqumber, M. A. A. (2023) · Healthcare · doi:10.3390/healthcare11131946 · Cited by 2,338
Distribution of antibiotic resistance genes in the environment
Zhuang, M., Achmon, Y., Cao, Y., Liang, X., Chen, L., Wang, H., Siame, B. A., & Leung, K. Y. (2021) · Environmental Pollution · doi:10.1016/j.envpol.2021.117402 · Cited by 422
Hammoudi Halat, D., & Ayoub Moubareck, C. (2020) · Antibiotics · doi:10.3390/antibiotics9040186 · Cited by 287
Xiong, Y., Han, Y., Zhao, Z., Gao, W., Ma, Y., Jiang, S., Wang, M., Zhang, Q., Zhou, Y., & Chen, Y. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s340652 · Cited by 22
Metadata
- Authors
- Suay-García, B., & Pérez-Gracia, M. T.
- Venue
- Antibiotics
- Publisher
- MDPI AG
- Published
- 2019-08-19
- Volume
- 8
- Issue
- 3
- Pages
- 122
- ISSN
- 2079-6382 (ISSN-L)
- OpenAlex
- W2969382641
- Cited by
- 344
- References
- 84
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.